GLP-1 out-of-pocket cost statistics for 2026 in the US

How to read a GLP-1 price quote

List price, also called wholesale acquisition cost or WAC, is the manufacturer's price to wholesalers before rebates. It can affect deductible and coinsurance calculations, but it is not necessarily the amount a cash customer pays. A pharmacy cash quote may be higher or lower, and an insurance claim may use a negotiated amount that is never shown to the patient. A manufacturer self-pay offer is a separate route. It may require an eligible prescription, a named pharmacy pathway, a particular device, a refill interval, or commercial insurance status. Cash-program payments generally do not count toward an insurance deductible or annual out-of-pocket maximum, so compare the immediate price with the value of using insurance later in the year.

Why insurance coverage can change the answer

Coverage is often easier to obtain for a medicine prescribed for type 2 diabetes than for a weight-management medicine, but each plan sets its own formulary and approval rules. Prior authorization means the insurer asks for advance documentation before it will pay. Step therapy means it may require a person to try another treatment first. KFF found that 57% of insured past or current GLP-1 users said insurance paid part of the cost and they paid the rest. Another 24% said insurance paid the full cost, while 19% said they paid the full cost themselves. That range explains why an advertised $25 amount should not be treated as a typical insurance copay. A Peterson-KFF analysis found people with large-employer coverage paid nearly $70 monthly on average for covered semaglutide. It is useful context, not a forecast. A deductible reset, coinsurance percentage, non-covered diagnosis, or denied authorization can produce a much larger amount.

Medicare access has a limited new route

On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge nationwide. Eligible Medicare Part D beneficiaries can receive specified weight-management products for a $50 monthly copay through December 31, 2027. The program currently includes Wegovy injection and tablets, Foundayo, and Zepbound KwikPen, rather than Zepbound single-dose pens or vials. The Bridge payment is outside the usual Part D payment and coverage flow. It does not count toward the Part D deductible or annual true out-of-pocket limit. People using Wegovy for an already coverable cardiovascular indication, or Zepbound for obstructive sleep apnea, may instead need their plan to assess coverage through the normal Part D process.

Higher doses can change Zepbound self-pay costs

Lilly's Zepbound KwikPen pricing is dose-specific. The listed regular 28-day self-pay prices are $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, or 15 mg. An eligible purchase offer can bring 7.5 mg and higher to $449, but the refill must be completed within 45 days to continue that offer. That condition has a real budgeting effect. A delayed refill or prescription change can affect the next price. Before a dose change, ask the pharmacy for the exact cash total and ask whether the current program conditions still apply.

Long-term treatment changes the affordability calculation

Wegovy and Zepbound are approved to reduce excess body weight and help maintain weight reduction over the long term. For that reason, the initial cash offer is only part of the financial decision. A sustainable plan may include the later dose price, clinician visits, laboratory work when ordered, nutrition support, and the possibility of insurance changes. In the 68-week STEP 1 trial, semaglutide 2.4 mg produced substantial average weight loss. In the extension, participants who stopped semaglutide regained an average 11.6 percentage points of body weight during the next year after losing 17.3% while on treatment. Put plainly, the group regained about two-thirds of the weight it had lost. In SURMOUNT-1, average weight change at 72 weeks with tirzepatide was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared with 3.1% with placebo. At a starting weight of 250 pounds, 15% is about 38 pounds and 20.9% is about 52 pounds. These are study averages under trial conditions, not a promise of a particular result. SURMOUNT-5 found average 72-week weight change of 20.2% with tirzepatide and 13.7% with semaglutide in its study population. The difference does not decide the right medicine for one person. Tolerability, approved use, health history, coverage, and the cost a household can sustain can matter as much as a trial average.

Safety and lower-cost alternatives need careful discussion

Common side effects in trials include nausea, diarrhea, constipation, vomiting, and abdominal discomfort. FDA labels also carry a boxed warning about thyroid C-cell tumors observed in rodents. Wegovy and Zepbound are contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A low advertised price for compounded semaglutide or tirzepatide does not establish that a product is equivalent to an FDA-approved medicine. The FDA says compounded products are not FDA-approved versions of Wegovy, Ozempic, Zepbound, or Mounjaro and has reported concerns including dosing errors, adverse-event reports, and semaglutide salt forms that differ from the approved active ingredient. A pharmacist or prescriber can help assess a specific product and its source.

A practical call list before starting or refilling

Ask the insurer whether the medicine is on the formulary for the diagnosis written on the prescription. Ask whether prior authorization, step therapy, or a quantity-limit exception applies. Then ask for the price before and after the deductible, and whether the charge is a flat copay or coinsurance, meaning a percentage of the allowed price. Ask the pharmacist to run the prescription through insurance before deciding whether a self-pay offer is cheaper. Confirm the exact device, dose, pharmacy, fill length, and refill deadline. Keep authorization letters and note their expiration dates, because a previous approval may not renew automatically. Lina is a GLP-1 companion app for people using Wegovy, Mounjaro, Ozempic, Zepbound, Saxenda, and related medications. It helps users track doses, side effects, meals, weight, protein, hydration, and habits in one place. It is a wellness tracking companion, not a medical device or a substitute for medical advice.